Product category:
Clinical chemistry analysis
News Release from: Siemens Healthcare Diagnostics | Subject: DCA 2000+
Edited by the Laboratorytalk Editorial
Team on 17 November 2006
Importance of HbA1c testing in diabetes
Bayer Diagnostics's portable DCA2000+ analyser can help counter the increased risk of dementia in Type 2 diabetes patients by promoting improved glycaemic control at the point of care
Study findings presented at the 10th International Conference of Alzheimer's Disease and Related Disorders suggest that patients aged 50 or over with Type 2 diabetes have an increased risk of developing dementia or Alzheimer's disease when their glycaemic (blood sugar) levels are poorly controlled The study, presented to delegates at the conference in the form of an abstract, found that Type 2 diabetes patients with HbA1c levels in excess of 15% have a 78% greater risk of developing dementia, Alzheimer's disease or cognitive decline in the next decade than patients who control their condition more effectively
This article was originally published on Laboratorytalk on 27 Mar 2006 at 8.00am (UK)
Related stories
Management of diabetes in the Asian community
A campaign has been recently been launched in the UK to make healthcare professionals more aware of the lower risk thresholds for heart disease and diabetes in their South Asian patients
Urine albumin measurement in intensive care
Bayer Diagnostics DCA 2000+ portable microalbuminuria and HbA1c analyser has played a pivotal role in a recent study conducted at University Hospital Birmingham Foundation NHS Trust
Those with very poor glycaemic control whose HbA1c levels exceed 10% were also found to be at increased risk of incident dementia.
HbA1c (also known as glycosylated haemoglobin) is a blood test that provides a history of a patient's blood glucose levels over a period of 8-12 weeks.
This test is now easy to accomplish at the point of care using the portable DCA 2000+ analyser from Bayer Diagnostics (a division of Bayer HealthCare).
The UK Department of Health recommends that all people with diabetes should have their HbA1c measured at least twice a year, and it has been shown that immediate feedback of results strongly motivates patients to improve their glycaemic control.
Bayer's DCA 2000+ is able to detect even the smallest changes in a patient's HbA1c, taking only six minutes to produce a highly accurate result from just 1ul of capillary/venous blood.
Such immediacy creates an ideal opportunity for results to be discussed directly with patients during the course of a single consultation.
This enhances patients' sense of empowerment by directly demonstrating the effects that changes in medication, diet and/or lifestyle have made to their condition.
Having HbA1c results available during the course of consultations helps to inform therapeutic decisions for patients with Type 2 diabetes, enabling steps to be taken that may reduce the risk of them developing dementia in later life.
• Siemens Healthcare Diagnostics: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
